Theravance Biopharma (TBPH) Net Cash Flow Growth (3y) (2017 - 2026)
Theravance Biopharma (TBPH) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Theravance Biopharma |
846.10 Mn |
451.44 Mn |
- |
45.63% |
| Date | Value |
|---|
| Mar 31, 2026 |
45.63% |
| Dec 31, 2025 |
-26.14% |
| Sep 30, 2025 |
47.58% |
| Jun 30, 2025 |
202.29% |
| Mar 31, 2025 |
154.70% |
| Dec 31, 2024 |
34.96% |
| Sep 30, 2024 |
34.97% |
| Jun 30, 2024 |
-27.70% |
| Mar 31, 2024 |
-23.99% |
| Dec 31, 2023 |
-103.69% |
| Sep 30, 2023 |
-43.59% |
| Jun 30, 2023 |
28.87% |
| Mar 31, 2023 |
-33.93% |
| Dec 31, 2022 |
175.04% |
| Sep 30, 2022 |
-121.56% |
| Jun 30, 2022 |
47.01% |
| Mar 31, 2022 |
26.59% |
| Dec 31, 2021 |
-28.33% |
| Sep 30, 2021 |
-215.80% |
| Jun 30, 2021 |
83.09% |
